Customize your JAMA Network experience by selecting one or more topics from the list below.
In the Brief Report titled “Timing of Loading Dose of Atorvastatin in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes: Insights from the SECURE-PCI Randomized Clinical Trial,”1 published online September 24, 2018, there were errors in the Abstract, Figure 1, Table, and Author Contributions. The Conclusions and Relevance section of the Abstract should read “In patients with ACS undergoing PCI, periprocedural loading doses of atorvastatin appeared to reduce the rate of MACE at 30 days, most clearly in patients with ST-segment elevation myocardial infarction. This beneficial effect seemed to be preserved and consistent, irrespective of the timing of atorvastatin administration, including within 2 hours before PCI.” In the Table, row “Stent deployment pressure” should have footnotes “a,b” at the end. In the first row of Figure 1B, the 95% CI line should stop at 0.92. In the third row, the 95% CI line should stop at 0.99, and the P value should read .045. In the fourth row of Figure 1C, the hazard ratio should be 1.22. The final sentence of the Conclusions section should read “Considering the safety of statins, treating patients with ACS, in particular with STEMI, with a loading dose of statin as early as possible before PCI is a reasonable approach that may improve short-term clinical outcomes.” Finally, the Author Contributions should read “Drs Lopes and Berwanger had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.” This article was corrected online.
Errors in Abstract, Figure 1, Table, Conclusion, and Author Contributions. JAMA Cardiol. 2018;3(11):1131. doi:10.1001/jamacardio.2018.3778
Create a personal account or sign in to: